In a nutshell This study is investigating how well nivolumab (Opdivo) works with DA-REPOCH chemotherapy for treating aggressive B-cell non-Hodgkin's lymphoma (NHL). The primary outcome to be measured is 2-year survival without disease progression after treatment. This study is being conducted in Columbus, OH, in the United States. The...
Read MorePerformance status -2 – Symptomatic, 50 in bed Posts on Medivizor
Searching for participants with high risk relapsed or unresponsive Hodgkin lymphoma to try a treatment combination.
In a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...
Read MoreLooking for newly diagnosed patients with acute myelogenous leukemia to test a chemotherapy combination
In a nutshell This trial is investigating the effectiveness of adding chemotherapy drug venetoclax to a standard chemotherapy treatment for patients with acute myelogenous leukemia (AML). The main outcome for this study would be the maximum amount of the drug that gives the most benefits to patients and the effectiveness of the drug. This study...
Read MoreLooking for patients with previously untreated mantle cell lymphoma to test a treatment combination
In a nutshell This phase 3 study is evaluating the effectiveness and safety of two different chemotherapy regimens for patients with mantle cell lymphoma (MCL). The main outcome to be measured will be the number of patients who survive without tumor growth or spread. This study is recruiting in Las Vegas, Nevada in the U.S. The details MCL is an...
Read MoreSearching for patients with recurrent or non-responsive lymphoma to try this new treatment option
In a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...
Read MoreSearching for patients with untreated small lymphocytic lymphoma to test combined immunotherapy
In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for SLL include...
Read MoreSearching for patients with untreated chronic lymphocytic leukemia to test combined immunotherapy
In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for chronic lymphocytic leukemia (CLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for CLL...
Read MoreLooking for young patients with non-Hodgkin’s lymphoma to test a treatment combination
In a nutshell This phase 3 trial is comparing the effectiveness of ibrutinib (Imbruvica) plus chemotherapy versus chemotherapy alone in children and young adults with B-cell non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be survival without cancer returning, growing or spreading. The details Ibrutinib is a targeted therapy...
Read MoreLooking for patients with chronic lymphocytic leukemia to test acalabrutinib-obinutuzumab combination
In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for chronic lymphocytic leukemia (CLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona,...
Read MoreLooking for patients with small lymphocytic lymphoma to test acalabrutinib-obinutuzumab combination
In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona, Jacksonville,...
Read MoreLooking for patients with relapse/unresponsive lymphoma to test a treatment combination
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read MoreSearching for patients with previously untreated DLBCL to try this new treatment combination
In a nutshell This study is comparing the effectiveness of R-CHOP chemotherapy with or without enzastaurin (Kinenza) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The main outcome to be measured will be overall survival at the end of the study. The details The current standard first-line treatment for DLBCL is R-CHOP...
Read More
